Compare NVNI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVNI | IFRX |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | Brazil | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 86.0M |
| IPO Year | N/A | 2017 |
| Metric | NVNI | IFRX |
|---|---|---|
| Price | $3.67 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 162.1K | ★ 2.3M |
| Earning Date | 09-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,250,627.00 | $73,729.00 |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | $15.02 | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1491.58 | N/A |
| 52 Week Low | $1.44 | $0.71 |
| 52 Week High | $121.90 | $2.77 |
| Indicator | NVNI | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 42.22 |
| Support Level | $3.32 | $1.04 |
| Resistance Level | $3.00 | $1.12 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 63.70 | 35.88 |
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.